SURF News and Press, Surface Oncology Inc. From 06/04/21

Senseonics Holdings SENS +34% on the study results for glucose monitoring system.Windtree Therapeutics (WINT) +28%.The9 Limited NCTY +18% on Montcrypto acquisition.SemiLEDs Corporation (LEDS) +16%.Q&K International Group Limited (QK) +15%.Core Laboratories N.V. (CLB) +...

Preliminary Data for SRF617 Show Good Tolerability and Promise in Combination Approaches Company to Hold Webcast to Review Data from Ongoing SRF388 and SRF617 Phase 1 Clinical Studies on Friday, June 4 th at 8:00 a.m. ET CAMBRIDGE, Mass., June 04, 2021 (GLOBE N...

CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced a clinical trial collaboration with Roche to evaluate SRF388, ...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Buying a stock means taking a chance that you'll lose money, so that your money will have a chance to grow. Thankfully, it's not possible to lose more money than it costs to buy the shares in the first place, though it is possible to make far more than your initial investment. So, by seedin...

“We are bullish on the cell and gene therapy space,” noted BTIG analyst Justin Zelin highlighting the importance of stock picking in the area given “the limited targets and indications to market.”In the area of cell therapy, Zelin initiates the coverage on six comp...

Surface Oncology (SURF): Q1 GAAP EPS of -$0.37 beats by $0.04.Revenue of $1.63M (-95.8% Y/Y) beats by $0.38M.As of March 31, 2021, cash, cash equivalents and marketable securities were $171.0 million, compared to $175.1 million on December 31, 2020. The company continues to pro...

CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first qua...

SRF388 Phase 1 Update to be Presented at American Society for Clinical Oncology Annual Meeting Company to Hold Webcast to Review Data from Ongoing SRF388 and SRF617 Phase 1 Clinical Studies on Friday, June 4 th at 8:00 a.m. ET CAMBRIDGE, Mass., April 28, 2021 (...

CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today the appointment of Henry Rath as chief business officer, and ...